Drugs / ALN-HBV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02826018 Comparator | Jun 2016 → Oct 2017 | chronic hepatitis B virus infection | Alnylam Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-HBV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826018 ↗ |
| Modality | Small interfering RNA (siRNA) | “small-interfering RNAs that target HBx” PMID 37290591 ↗ Jun 2023 |
| Route | Subcutaneous | “Ascending doses of ALN-HBV by subcutaneous (sc) injection” NCT02826018 ↗ |